利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.022 秒)

    MODIFIED VACCINIA ANKARA VIRUS VARIANT
    1.
    发明申请
    MODIFIED VACCINIA ANKARA VIRUS VARIANT 审中-公开
    改良的VACCINIA ANKARA VIRUS变种

    公开(公告)号：US20120328650A1

    公开(公告)日：2012-12-27

    申请号：US13588217

    申请日：2012-08-17

    申请人： PAUL CHAPLIN ,  PAUL HOWLEY ,  CHRISTINE MEISINGER-HENSCHEL

    发明人： PAUL CHAPLIN ,  PAUL HOWLEY ,  CHRISTINE MEISINGER-HENSCHEL

    IPC分类号： A61K39/275 ,  A61P31/12 ,  A61K39/295

    CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K39/285 ,  A61K48/00 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/545 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/24121 ,  C12N2710/24143 ,  C12N2740/16322

    摘要： The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes when compared to DNA prime/vaccinia virus boost regimes. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus.

    摘要翻译： 本发明提供了一种减毒病毒，其来源于改良的痘苗病毒安卡拉病毒，其中MVA-BN病毒或其衍生物在痘苗病毒原/疫苗病毒增强方案中诱导至少基本相同的免疫水平， DNA原核/痘苗病毒增强体系。 它还描述了源自该病毒的重组病毒和病毒或其重组体作为药物或疫苗的用途。 提供了一种方法，用于在可能被免疫损害的个体中诱导免疫应答，接受抗病毒治疗或具有疫苗病毒的预先存在的免疫。

    MODIFIED VACCINIA ANKARA VIRUS VARIANT AND CULTIVATION METHOD
    2.
    发明申请
    MODIFIED VACCINIA ANKARA VIRUS VARIANT AND CULTIVATION METHOD 有权
    改良的VACCINIA安卡拉病毒变种和培养方法

    公开(公告)号：US20110217757A1

    公开(公告)日：2011-09-08

    申请号：US13106176

    申请日：2011-05-12

    申请人： PAUL CHAPLIN ,  PAUL HOWLEY ,  CHRISTINE MEISINGER-HENSCHEL ,  INGMAR RATHE ,  EVA FELDER ,  KARL HELLER

    发明人： PAUL CHAPLIN ,  PAUL HOWLEY ,  CHRISTINE MEISINGER-HENSCHEL ,  INGMAR RATHE ,  EVA FELDER ,  KARL HELLER

    IPC分类号： C12N7/02

    CPC分类号： A61K39/285 ,  A61K39/12 ,  A61K48/00 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/545 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/24134 ,  C12N2710/24143 ,  C12N2710/24151 ,  C12N2740/16322

    摘要： The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost inoculation regimen. The present invention relates to a method of virus amplification in primary cells which are cultivated in a serum free medium. Viruses produced by this method are advantageously free of any infectious agents comprised in animal sera.

    摘要翻译： 本发明提供一种减毒病毒，其衍生自改良的痘苗安卡拉病毒，其特征在于丧失其在人细胞系中繁殖复制的能力。 它还描述了源自该病毒的重组病毒和病毒或其重组体作为药物或疫苗的用途。 提供了一种方法，用于在可能被免疫损害的个体中诱导免疫应答，接受抗病毒治疗或具有疫苗病毒的预先存在的免疫。 此外，提供了一种用于在痘苗病毒原/痘苗病毒加强接种方案中施用治疗有效量的病毒或其重组体的方法。 本发明涉及在无血清培养基中培养的原代细胞中的病毒扩增方法。 通过该方法产生的病毒有利地不含动物血清中包含的任何传染性物质。

    MODIFIED VACCINIA ANKARA VIRUS VARIANT AND CULTIVATION METHOD
    3.
    发明申请
    MODIFIED VACCINIA ANKARA VIRUS VARIANT AND CULTIVATION METHOD 有权
    改良的VACCINIA安卡拉病毒变种和培养方法

    公开(公告)号：US20120276613A1

    公开(公告)日：2012-11-01

    申请号：US13544201

    申请日：2012-07-09

    申请人： PAUL CHAPLIN ,  PAUL HOWLEY ,  CHRISTINE MEISINGER-HENSCHEL ,  INGMAR RATHE ,  EVA FELDER ,  KARL HELLER

    发明人： PAUL CHAPLIN ,  PAUL HOWLEY ,  CHRISTINE MEISINGER-HENSCHEL ,  INGMAR RATHE ,  EVA FELDER ,  KARL HELLER

    IPC分类号： C12N7/04 ,  C12N7/00

    CPC分类号： A61K39/285 ,  A61K39/12 ,  A61K48/00 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/545 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/24134 ,  C12N2710/24143 ,  C12N2710/24151 ,  C12N2740/16322

    摘要： The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost innoculation regimen. The present invention relates to a method of virus amplification in primary cells which are cultivated in a serum free medium. Viruses produced by this method are advantageously free of any infectious agents comprised in animal sera.

    摘要翻译： 本发明提供一种减毒病毒，其衍生自改良的痘苗安卡拉病毒，其特征在于丧失其在人细胞系中繁殖复制的能力。 它还描述了源自该病毒的重组病毒和病毒或其重组体作为药物或疫苗的用途。 提供了一种方法，用于在可能被免疫损害的个体中诱导免疫应答，接受抗病毒治疗或具有疫苗病毒的预先存在的免疫。 此外，提供了一种用于在痘苗病毒原/痘苗病毒增强接种方案中施用治疗有效量的病毒或其重组体的方法。 本发明涉及在无血清培养基中培养的原代细胞中的病毒扩增方法。 通过该方法产生的病毒有利地不含动物血清中包含的任何传染性物质。

    MODIFIED VACCINIA ANKARA VIRUS VARIANT AND CULTIVATION METHOD
    4.
    发明申请
    MODIFIED VACCINIA ANKARA VIRUS VARIANT AND CULTIVATION METHOD 有权
    改良的VACCINIA安卡拉病毒变种和培养方法

    公开(公告)号：US20100279386A1

    公开(公告)日：2010-11-04

    申请号：US12836324

    申请日：2010-07-14

    申请人： PAUL CHAPLIN ,  PAUL HOWLEY ,  CHRISTINE MEISINGER-HENSCHEL ,  INGMAR RATHE ,  EVA FELDER ,  KARL HELLER

    发明人： PAUL CHAPLIN ,  PAUL HOWLEY ,  CHRISTINE MEISINGER-HENSCHEL ,  INGMAR RATHE ,  EVA FELDER ,  KARL HELLER

    IPC分类号： C12N7/00 ,  C12N7/02

    CPC分类号： A61K39/285 ,  A61K39/12 ,  A61K48/00 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/545 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/24134 ,  C12N2710/24143 ,  C12N2710/24151 ,  C12N2740/16322

    摘要： The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost innoculation regimen. The present invention relates to a method of virus amplification in primary cells which are cultivated in a serum free medium. Viruses produced by this method are advantageously free of any infectious agents comprised in animal sera.

    摘要翻译： 本发明提供一种减毒病毒，其衍生自改良的痘苗安卡拉病毒，其特征在于丧失其在人细胞系中繁殖复制的能力。 它还描述了源自该病毒的重组病毒和病毒或其重组体作为药物或疫苗的用途。 提供了一种方法，用于在可能被免疫损害的个体中诱导免疫应答，接受抗病毒治疗或具有疫苗病毒的预先存在的免疫。 此外，提供了一种用于在痘苗病毒原/痘苗病毒增强接种方案中施用治疗有效量的病毒或其重组体的方法。 本发明涉及在无血清培养基中培养的原代细胞中的病毒扩增方法。 通过该方法产生的病毒有利地不含动物血清中包含的任何传染性物质。

    PHENOTYPIC AND GENOTYPIC DIFFERENCES OF MVA STRAINS
    10.
    发明申请
    PHENOTYPIC AND GENOTYPIC DIFFERENCES OF MVA STRAINS 审中-公开
    MVA菌株的PHENOTYPIC和遗传差异

    公开(公告)号：US20110172407A1

    公开(公告)日：2011-07-14

    申请号：US13025271

    申请日：2011-02-11

    申请人： PAUL CHAPLIN

    发明人： PAUL CHAPLIN

    IPC分类号： C07H21/04

    CPC分类号： C12Q1/701

    摘要： The present invention provides kits and methods to screen viral nucleic acids for a profile of genetic deletions and mutations, optionally in combination with one or more assays for viral replication and/or attenuation capacity.

    摘要翻译： 本发明提供了用于筛选病毒核酸以用于遗传缺失和突变分布的试剂盒和方法，任选地与用于病毒复制和/或衰减能力的一种或多种测定组合。